Insulin lispro lowers postprandial glucose in prepubertal children with diabetes

被引:70
作者
Deeb, LC
Holcombe, JH
Brunelle, R
Zalani, S
Brink, S
Jenner, M
Kitson, H
Perlman, K
Spencer, M
机构
[1] Childrens Clin, Tallahassee, FL 32308 USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] New England Diabet & Endocrinol Ctr, Waltham, MA USA
[4] Childrens Hosp Western Ontario, London, ON, Canada
[5] Childrens Hosp, Vancouver, BC, Canada
[6] Hosp Sick Children, Vancouver, BC, Canada
[7] Int Diabet Ctr, Minneapolis, MN USA
关键词
insulin lispro; children; blood glucose control;
D O I
10.1542/peds.108.5.1175
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. This study compared the glucose-lowering effect of insulin lispro, given before or after meals, with regular human insulin given before meals in prepubertal children with diabetes. Research Design and Methods. A 3-way crossover, open-label study involving 61 prepubertal children (ages 2.9-11.4 years) with type 1 diabetes. The children were randomly assigned to receive regular human insulin 30 to 45 minutes before meals, insulin lispro within 15 minutes before or immediately after meals, combined with basal insulin. Each treatment lasted 3 months. Hemoglobin A(1c) levels and home glucose monitoring profiles were measured at the end of each treatment period. Results. Treatment with insulin lispro before breakfast resulted in lower 2-hour postprandial glucose values than regular human insulin (11.7 +/- 4.4 mmol/L vs 15.0 +/- 5.4 mmol/L). Similarly, insulin lispro given before dinner resulted in lower blood glucose values 2 hours postprandially (8.8 +/- 5.0 mmol/L vs 10.8 +/- 5.4 mmol/L) than regular human insulin. When insulin lispro was administered after meals, the 2-hour glucose levels were between those seen with either insulin lispro or regular human insulin given before meals. The number and types of adverse events, the rates of hypoglycemia, and the HbA(1c) levels did not differ among the 3 therapies. Conclusions. In prepubertal children, insulin lispro given before meals is safe and significantly lowers postprandial glucose levels after breakfast and dinner compared with regular human insulin, and insulin lispro given after the meal provides similar benefits as regular human insulin before the meal.
引用
收藏
页码:1175 / 1179
页数:5
相关论文
共 18 条
  • [1] Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment
    Anderson, JH
    Brunelle, RL
    Koivisto, VA
    Pfutzner, A
    Trautmann, ME
    Vignati, L
    DiMarchi, R
    Bowen, KM
    Cameron, DP
    Nankervis, AJ
    Roberts, AP
    Zimmet, P
    Borkenstein, MH
    Schernthaner, G
    Waldhausl, WK
    DeLeeuw, IH
    Fery, F
    Scheen, A
    Somers, G
    Fettes, IM
    Tildesley, HD
    Toth, EL
    Viikari, J
    Altman, JJ
    Bougneres, PF
    Drouin, P
    Fossati, P
    Guillausseau, PJ
    Marechaud, E
    Riou, JP
    Selam, JL
    Vialettes, PB
    Beyer, J
    Federlin, K
    Fussganger, RD
    Gries, FA
    Jastram, HU
    Koop, I
    Landgraf, R
    Rosak, C
    Schatz, H
    SchulzeSchleppinghoff, B
    Seif, FJ
    Stoeckmann, F
    Karasik, A
    Weitzman, S
    Andreani, D
    Bompiani, G
    Crepaldi, G
    Giorgino, R
    [J]. DIABETES, 1997, 46 (02) : 265 - 270
  • [2] Brackenridge B, 1996, SWEET KIDS BALANCE D
  • [3] Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes
    Brunelle, RL
    Llewelyn, J
    Anderson, JH
    Gale, EAM
    Koivisto, VA
    [J]. DIABETES CARE, 1998, 21 (10) : 1726 - 1731
  • [4] Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: A Belgian experience
    Dorchy, H
    Roggemans, MP
    Willems, D
    [J]. DIABETES CARE, 1997, 20 (01) : 2 - 6
  • [5] Strategies toward improved control during insulin lispro therapy in IDDM - Importance of basal insulin
    Ebeling, P
    Jansson, PA
    Smith, U
    Lalli, C
    Bolli, GB
    Koivisto, VA
    [J]. DIABETES CARE, 1997, 20 (08) : 1287 - 1289
  • [6] Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin
    Fineberg, NS
    Fineberg, SE
    Anderson, JH
    Birkett, MA
    Gibson, RG
    Hufferd, S
    [J]. DIABETES, 1996, 45 (12) : 1750 - 1754
  • [7] Garg SK, 1996, DIABETIC MED, V13, P47, DOI 10.1002/(SICI)1096-9136(199601)13:1<47::AID-DIA999>3.0.CO
  • [8] 2-M
  • [9] Drug therapy - Insulin lispro
    Holleman, F
    Hoekstra, JBL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) : 176 - 183
  • [10] *INT DIAB CTR, 1995, STAG DIAB MAN OWN MA, P20